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Numerous studies have shown that the risk of Alzheimer’s disease (AD) is associated with the dose of the €4  allele of 
apolipoprotein E (ApoE). However, more than one third of AD patients lack ~4 and many persons having ~4 survive 
cognitively intact to old age. We evaluated the lifetime risk of disease in 3,999 first-degree relatives of 549 probands 
who met the criteria for probable or definite AD and whose ApoE genotypes were known. ApoE genotypes for 
relatives were not determined. After age 65 the risk among relatives was proportional, as much as 7 to 10% at age 
85, to the number of ~4 alleles present in the proband. Risks to relatives of ApoE 212 and 2/3 probands were nearly 
identical at all ages to risks for relatives of ApoE 3 / 3  probands. The expected proportion of relatives having at least 
one € 4  allele was calculated for each genotype group based on the distribution of parents, sibs, and offspring in the 
sample. Among relatives in the ApoE 3 / 3  group, the lifetime risk for AD by age 90 was three times greater than the 
expected proportion of ~4 carriers, suggesting that factors other than ApoE contribute to AD susceptibility. Further- 
more, the 44% risk of AD by age 93 among relatives of ApoE 414 probands indicates that as many as 50(%’ of people 
having at least one ~4 allele do  not develop AD. We also found that among male relatives, risk of AD in the ApoE 
314 group was similar to that for the ApoE 313 group but significantly less than the risk for the ApoE 414 group. 
In contrast, among female relatives the risk for the ApoE 314 group was nearly twice that for the ApoE 3 / 3  group 
and identical to the risk for the ApoE 414 group. These findings are consistent with a sex-modification effect of the 
E4 isoform on disease susceptibility. 
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Alzheimer’s disease (AD) is a degenerative disorder 
that causes loss of memory and cognition in more than 
6 to 10% of the population over the age of 65 11, 
21. Increased risk of disease is associated with several 
epidemiological risk factors (for a review see 121); how- 
ever, none of these has been consistently observed. 
The  strongest predictors of disease risk are age and 
family history of AD. 
Molecular genetic studies have implicated at least 
four genes in disease pathogenesis. Mutations in three 
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of these, the chromosome 2 I gene encoding P-amyloid 
precursor protein, the AD3 gene on chromosome 14, 
and the SMT2 gene on chromosome 1, account for a 
relatively small group of patients with autosomal domi- 
nantly transmitted disease that manifests usually before 
the age of 65 13-71. The e2  and e4 alleles of the 
apolipoprotein E (ApoE) gene are in linkage disequilib- 
rium with A D  in patients from various parts of the 
world with early onset [S] and late onset [9] of symp- 
toms (see [ l o }  for an extensive list of studies). The 
biological basis for these associations is unknown. 
In vitro experiments suggest that the E3 (and E2) 
isoforms interact metabolically with microtubule- 
associated proteins in a manner different from the E4 
isoform Ell, 12). However, because neurons do not 
express ApoE messenger RNA (mRNA) and the cellu- 
lar trafficking of ApoE in neurons is poorly under- 
stood, this explanation for the role of ApoE in A D  
pathogenesis is still speculative. Alternatively, aberrant 
interaction between ApoE and f3-amyloid may be a 
critical step in the disease [ 131. 
In spite of the compelling evidence for a dose effect 
of e4 on risk and age at onset of A D  [ 141, the sensitiv- 
ity and specificity of the association are modest 1 1  51. 
Here, sensitivity refers to the proportion of individuals 
with e4 among those who will develop AD; specificity 
refers to the proportion of individuals without e4 
among those who will not develop disease. Reduced 
sensitivity of ~4 for A D  suggests that the disorder in 
many persons is caused by factors independent of 
ApoE. The observation that not all persons who have 
the ~4 allele develop A D  (i.e., reduced specificity) sug- 
gests that either the effect of € 4  is modulated by other 
risk factors or such persons in whom the disease is 
apparently nonpenetrant have not survived to their 
eventual onset age. 
To address the questions of sensitivity and specihcity 
of ApoE on risk of AD, we investigated the relation- 
ship between lifetime risk of disease, ApoE genotype, 
and sex in a group of 549 families in which the pro- 
bands met rigorous diagnostic criteria and were geno- 
typed for ApoE. 
Materials and Methods 
Su6jectnh 
Two patient cohorts were recruited for this study. One group 
includes 378 participants in the Multi-Institutional Research 
in Alzheimer Genetic Epidemiology (MIRAGE) Study. M1- 
RAGE centers are tertiary care units that evaluate patients 
referred for a memory disorder. The groups participating in 
this study are the Alzheimer's Disease Resource and Referral 
Center at the Boston University Medical Center (BU); the 
Geriatric Research Education and Clinical Center (GRECC), 
Edith Nourse Rogers Memorial Veterans Hospital, Bedford, 
MA (Bedford); the Wesley Woods Center at Emory Univer- 
sity, Atlanta, G A  (Emory); the Memory Disorders Unit of 
the Massachusetts General Hospital (MGH); the Wien Cen- 
ter at Mount Sinai Medical Center in Miami Beach, FL (Mi- 
ami ); the Southern California Alzheimer's Disease Diagnostic 
and Treatment Center at the Rancho Los Amigos Medical 
Center, Downey, CA (USC); and the Psychiatry Clinic at the 
Technical University of Munich, Germany (Munich). 
MIRAGE patients were consecutively ascertained from 
the clinic populations at each of the centers and underwent 
a rigorous diagnostic evaluation including a neurological ex- 
amination and appropriate neuropsychological, laboratory, 
and brain imaging tests. Eligible probands had a rating of 1 
(59 subjects) or 2 (319 subjects) on the A axis of the MI- 
RAGE AD rating scale 1161. These ratings correspond to 
National Institute of Neurological anJ Communicative Dis- 
orders and Stroke/ Alzheimer's Disease and Related Disor- 
ders Association (NINCDSIADRDA) criteria for definite 
(i.e., autopsy-confirmed) or probable AD, respectively [ 171. 
Interrater reliability of diagnosis among MIRAGE sites using 
this rating scale was found t o  be sufficiently high 1161. Infor- 
mation on family history of dementia among first-degree rela- 
tives (i.e., parents, siblings, and children) was collected from 
a primary informant (usually a spouse or  child, and occasion- 
ally a sibling) using standardized questionnaire instruments 
administered by direct or telephone interview. Multiple in- 
formants were sought to supplement and verify these re- 
sponses. Relatives were considered t o  be affected if they met 
criteria for ratings 1 to 4 on the MIRAGE AD rating scale. 
Ratings of 3 or 4 correspond to varying degrees of certainty 
in the diagnosis of possible AD. Additional details regarding 
patient sampling and evaluation can be found elsewhere 
tV. S. Rao and colleagues, unpublished manuscript, 1995). 
Of the 1,150 probable and definite AD patients at these 
centers for whom family history information was available, 
tissue samples for D N A  analysis were obtained for 59 autop- 
sied subjects and 319 subjects who were evaluated in the 
clinic between July 1993 and April 1905. Selected character- 
istics of the probands are given in Table 1. 
The second subjecr group was composed of 171 patients 
enrolled in a population-based study in the Netherlands [ 181. 
All of these patients had onset of symptoms before the age 
of 65 years and are thus considered to  have early-onset AD. 
Details of the study design and diagnostic criteria have been 
published [ l X ,  191. Probands were evaluated by two physi- 
cians who independently confirmed the diagnosis of probable 
AD using a standard protocol similar to NINCDSiADRDA 
and MIRAGE criteria. Our previous studies showed that life- 
time risk and patterns of familial aggregation of illness among 
first-degree relatives of these patients [ 181 were similar to 
results obtained from studies of MGH patients [20,  211. 
ApoE Ge~otypiiig 
The ApoE assay for the AD cases was performed by polymer- 
ase chain reaction (PCR) applying the methoJ of Wenharn 
and coworkers [221 or van Duijn and colleagues [8 ] .  The 
ApoE gene was amplified using conditions as described else- 
where [8, 251 tL. A. Farrer and colleagues, unpublished 
manuscript, 1995). The PCR product was digested with ei- 
ther H / ~ u  I or Cfa I following a standard procedure [ 2 4 ]  and 
fragments were separated on a standard 6':; nondenaturing 
polyacrylamide gel. ApoE genotype frequency data for the 
Dutch patient group have been reported [ 8 } .  
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Table I. Characteristics of Probands and First-Degree Relatitla by Site 
Probands Relatives 
No. of No. of Onset Age (yr) No. No. 
Site Males Females (mean ? std) Affected Unaffected 
Boston University 23 37 70.8 ? 8.0 22 443 
Emory 7 8 75.5 ? 6.1 16 75 
Massachusetts General Hospital 48 103 67.6 t 8.3 106 1,102 
Bed ford 27 0 64.2 ? 8.2 5 196 
Miami 4 13 74.0 t 8.1 1 1  127 
Munich 28 41 65.1 * 8.8 16 431 
Rotterdam 56 1 1 5  57.8 ? 5.0 112 1,073 
University of Southern California 14 23 67.2 ? 6.7 28 2 16 
Total 207 340 65.3 f 9.2 3 16 3,683 
Estimation of Lifetime Risk and Age  
at Onset Distribution 
The lifetime risk of dementia and the age at onset distribu- 
tion for first-degree relatives of the A D  probands were esti- 
mated using a maximum likelihood procedure [25] .  This 
method considers not only affected persons with known on- 
set ages and unaffected persons with known censoring ages 
(i.e., those persons typically included in a Kaplan-Meier sur- 
vival analysis [26]) ,  but also persons for whom onset age or 
censoring age data are missing. In this study. 35 affected and 
75 unaffected individuals (2.75%) of all relatives) were lack- 
ing these data but were able to be incorporated in the analy- 
sis. This method also allows for the possibilities that a propor- 
tion of relatives asymptomatic at the time of study may be 
susceptible and express the disease later in life and that some 
dead relatives may have died from causes unrelated to AD 
although symptoms may have developed had they survived. 
All lifetime risks, mean ages at onset, and survival distribu- 
tions reported here were estimated using this method. 
Parameter estimates and their standard errors for the esti- 
mated lifetime risk and mean onset age were compared be- 
tween subgroups of A D  relatives at the oldest age common 
to both groups. Since asymptotically these maximum likeli- 
hood statistics have normal distributions, a large sample Z 
statistic was used for these comparisons [27J Test-based con- 
fidence intervals for risk ratios were computed using this Z 
statistic. A log-rank statistic was used to test homogeneity of 
onset age distributions [28).  For the purpose of these analy- 
ses, probands were stratified by ApoE genotype. For some 
analyses, families of probands with an ApoE genotype of 212 
or 213 were combined with families whose probands were 
313, and families of probands with 214 were combined with 
314 families. Gender effects were evaluated by further strati- 
fication of the relatives by sex and sex of the proband. Inter- 
action of ApoE genotype and sex on lifetime risk of A D  was 
tested formally by proportional hazard regression analysis in 
the 77.25% of subjects who had known censoring ages [29]. 
Models were evaluated using the PHREG procedure of the 
SAS ~301. 
Distribution of ~4 among First-Degree Relatises 
To assess directly the proportion of the estimated lifetime 
risk of disease among relatives attributable to ApoE geno- 
type, one would need to have ApoE information on the rela- 
tives. This was not feasible because most parents and sibs are 
either deceased or  otherwise unavailable for study. Genotyp- 
ing children for ApoE is not warranted since most are too 
young to have expressed disease. However, the expected 
proportions of first-degree relatives of AD patients having at 
least one ApoE e4 allele can be derived from the conditional 
probabilities of the possible mating types among parents and 
spouses of the probands having a specified ApoE genotype. 
For these analyses, we modeled ApoE genotype as a two- 
allele system with frequencies p and q for the non-e4 (i.e., 
.52 and 83) and e4 alleles, respectively, and assumed that 
the frequency of the e4 allele in parental chromosomes not 
inherited by the proband was 0.135, that is, the same as in 
the general population t31). Because the 82  allele accounts 
for less than 8% of the polymorphism in the general popula- 
tion [31), its frequency was combined with that for e3. 
Hardy-Weinberg equilibrium among the allele frequencies 
was assumed. 
To calculate the proportion of a specific group of relatives 
( ix . ,  parents, sibs, or offspring) having the ApoE 314 or 414 
genotype, the conditional probability of each possible mating 
type was multiplied by the proportion of relatives having the 
genotype, and these products were summed over all possible 
matings. The expected proportions of parents, sibs, and off- 
spring having ApoE 314 and 414 genotypes are given in Table 
2. The expected proportion of first-degree relatives having 
at least one e4  allele was then determined in a two-step 
process. First, within each proband genotype group the ex- 
pected frequencies from Table 2 for each set of relatives 
were summed to calculate the total proportion of individuals 
having at least one e4 allele. Second, these proportions were 
adjusted for the relative frequencies of parents, sibs, and 
offspring in the sample. 
Results 
Over a life span of 76 years, the risk for dementia to 
first-degree relatives of all AD probands was 40.6 + 
4.3% (Table 3). The estimated mean onset age for 
affected relatives was 80.8 t 1.4 years. Stratification 
of the families by ApoE genotype of the proband re- 
vealed that relatives of probands having at least one ~4 
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Table 2. Expected Proportion of' First-Degree Reiatzi8e.i Hai,irig at Least Orie ApoE ~4 Allele 
Proportion of Relatives Having ApoE Genotype 
Parents Sibs Offspring 
Parents Spouse 
~ 
Proband's Possible Conditional Possible Conditional 
Genotype" Mating Probabilityb Genotype Probability X4 44 X4 44 x4 44 
xx xx x xx 
xx x x4 
x4 x x4 
Total 
x4 xx x x4 
xx x 44 
X I  x Xd 
x4 x 44 
Total 
xx 
X 4  
44 
xx 
x4 
44 
44 x4 x x4 
Xr'l x 44 
44  x 44 
xx 
Xd 
44 
P' 
P9 
0 
Total P 4  P 
"X = F Z  o r  ~ 3 .  
h p  = frequency of X (i.e., e 2  + ~ 3 ) ;  q = frequency c i f  F A ;  Hardy-Weinberg equilibrium assumed, therefore p + q = I 
Tablr .3. Estimated Lgetinie Riik r / f  A D  and the A g  at Onset Dictribi/tioii unioiig Fzrir-Degree Relatires o /AD Prohanth Stratifird 
by ApoE Genotype and among Coiitwl S14hjrm 
No. of Relatives 
No. of Oldest Onset Lifetime Risk Comparison Risk Mean Onser Age 
Probands Affected Unaffected Age ( y r )  (SE) (SE)J ( y r )  (SE) 
549 316 3,683 96 0.406 (0.0.Ij) 80.8 ( 1 . 4 )  
Group 
All 
E 2 2 l E  231E33 
E241E341C44 
225 95 1,508 06 0.360 (0.085) 0.274 (0.047) 8.3.7 ( 2 . 8 )  
324 22 1 2.175 93 0.453 (O.O.46) 0.453 (0.046) 79.7 (1 .2 )  
40 14 2'0 85 0 .178  (0 .053)  0.1% (0 .053)  -6.7 ( 2 . 5 )  
185 81 1,238 96 0.383 (0.092) 0.196 (0.02(>) 84.2 ( 2 . 7 )  
228 155 1,546 93 0.458 (0.056) 0.295 (0.020) 80.4 ( 1.4) 
86 61 562 91 0.442 (0.082) 0 .370  (0 .048)  ' J . 8  (2 .2)  _ _  
E 22lE 2 3  
t '33 
e 34 
F44 
"Risk at maximum age common t o  comparison groups (i.e., the smallest o f  the oldest onset ages); see text for groups being compared. 
allele had an 18Y greater risk of developing A D  by 
age 93 than did relatives of probands lacking ~4 ( Z  = 
2.72, p = 0.OO66). The  estimated mean onset ages of 
the two groups were not significantly different ( Z  = 
1.40, p = 0.16). These findings suggest that although 
the relative proportion of early- and late-onset cases is 
similar among relatives of probands with or without 
the e 4  allele, the risk of A D  is higher in relatives of 
e 4  probands for ages of 65  years and older (Fig 1 ) .  
The  relative risk for A D  by the age of 9.3 for those 
with an affcctcd relative with ~4 compared with those 
with an affected relative lacking ~4 is 1.65 t%".i con- 
fidence interval = 1.2-2.4). 
At every age after 65 years, the risk of A D  among 
relatives was proportional t o  the number of e 4  alleles 
present in the proband (Fig 2 ) .  At age 85 (the maxi- 
mum onset age among affected relatives common to 
all genotype groups) the cumulative incidence of A D  
among relatives of patients having ApoE genotype 
2 / 2  or 2 / 3  was not significantly different from the risk 
among relatives of ApoE 313 patients ( p  = 0.30). Rela- 
tives of probands having ApoE 3/.3 had a lifetime risk 
of 0.20 of developing A D  by age 85. h s k  of disease 
among relatives increased by 7 to 109; with the num- 
ber of € 4  ;tlleles in the proband; however, only the 
difference between the 313 and 314 groups was signifi- 
cant (313 vs 3/41 Z = 2.69, p = 0.0072; -314 vs 414: 
Z = 1.37, p = 0.17). I11 fact, the entire distributions 
for the ApoE 314 and 414 groups were not significantly 
different (log-rank x L  = 1.00, p = 0.32). Although 
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Fig  1 .  Estimated IIfetiine inciderzce of Afzhrinit.rj di.sease (AD)  
ill first-degree relatires of AD prohand ujieth ApoE 4 and ApoE 
11o)i-4 gemtypes. Vertical lines shouj statitlard errors at each 
age iialue for onset in aflected relatires. 
Table 3 suggests a trend of decreasing onset age among 
affected relatives with dose of ~4 in the proband, all 
pairwise comparisons between mean onset ages for rel- 
atives of 313, 314, and 414 probands were not signifi- 
cant. Lifetime risk and the onset age distribution were 
not estimated for relatives of the 10 ApoE 214 pro- 
bands because results from such a small sample would 
not be accurate. 
Estimates of the proportions of relatives having 
ApoE genotype 3 /3  or 3/4  (see Table 2) and the ob- 
served distribution of relatives were used to derive the 
expected proportion of relatives having at least one 
~4 allele (Table 4) .  Approximately 137f of the 1,319 
relatives of the A D  probands having ApoE 313 are 
predicted to be € 4  carriers. This estimate equals one 
half of the cumulative incidence of AD by age 90 in 
this group of relatives. These results indicate that famil- 
ial factors other than ApoE contribute to aggregation 
of A D  in this group of families. In contrast, among 
relatives of ApoE 314 and 414 probands, the expected 
proportions of € 4  carriers are 1.5 and 2.1 times greater, 
respectively, than the lifetime risk of AD. Therefore, 
even after allowing for the possibility of onset of dis- 
ease symptoms as late as age 30, between 34 and 5 1% 
of € 4  carriers are predicted to be cognitively normal. 
Comparisons of lifetime risk with the expected propor- 
tion of ~4 carriers were not done for parents and sibs 
separately because the life risks for these groups of 
relatives were not significanrly different, regardless of 
the ApoE genotype of the proband (data not shown). 
For each ApoE genotype, lifetime risks of A D  
among relatives of male and female probands were not 
significantly different at the comparison age of 82 years 
(Table 5) .  However, stratification of the relatives by 
sex revealed that among probands having ApoE 314, 
female relatives had approximately twice the lifetime 
risk as male relatives of developing AD by age 84 (Z 
= 3.92, p = 0.00009). The gender differences in risk 
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T d r  4. Conipnrisori o f  Expected Prupovtioii of Rdntiws Haifirig ApoE €4 with Lifetime R u k  of  A D  
Expected Proportion of Relatives Having 
Proband’s No. of Relatives ar Least 1 ApoE ~4 Allele Lifetime Kisk (SE) 
ApoE of AD in Relatives 
Genotype Parents Sibs Offspring Total Parents Sibs Offspring Total” at Age 00 
313 3 5 3  676 290 1,319 0.135 0.130 0.135 0.133 0.2.41 ( 0 . 0 3 5 )  
114 430 848 413 1,701 0.568 0.597 0.568 0.582 0..304 (0.042) 
4 4  160 327 1-56 623 1.0 0.813 1.0 0.902 0.430 (0.076) 
“Weighrrcl for sample sizes of parrnts, sibs, and offspring. 
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Table 5 .  Estimated Lifetime Risk of A D  among First-Degree Rekatii'es Stratifed by Sex of the P w b d d q  Se.x afthe Rdczttm, 
atzd ApoE Genotype of the Proband 
No. of Relatives Comparison.' 
Oldest Onset 
Group Affected Unaffected Age (yr) Lifetime Risk (SE) Age R ~ s k  (SE) 
Male probands 
E 3 3  34 458 96 0.573 (0.168) 82 0.134 (0.03 1) 
F 34 60 538 90 0.439 (0.078) 81 0.256 (0.034) 
E 4 4  20 206 82 0.283 (0.064) 82 0.283 (0.064) 
Female probands 
E 3 3  47 780 93 0.267 (0.070) 82 0.15 1 (0.026) 
E 34 95 1,002 93 0.477 (0.078) 82 0.248 (0.027) 
E44 41 356 91 0.527 (0.112) 82 0.328 (0.054) 
Male relatives 
E 3 3  28 640 96 0.334 (0.179) 0.140 (0.032) 
E 34 48 80 1 93 0.351 (0.090) " 84 0.170 (0.030) 
E44 27 27 1 91 0.526 (0.182) 84 0 . 3 3 0  (0.070) 
Female relatives 
E 3 3  5 3  596 93 0.374 (0.072) 84 0.206 (0 .033)  
E 34 107 739 92 0.538 (0.068) 84 0.348 (0.034) 
E44 34 271 85 0.409 (0.067) 8 4 0.374 (0.061) 
'See text for groups bring compared. 
for the relatives of ~3 and ~4 homozygotes were not 
significant (Z  = 1.44, p = 0.15 and Z = 0.47, p = 
0.64). Furthermore, Figure 3 shows that among male 
relatives the estimated risk for the ApoE 3/4 group 
was not different from the risk for the ApoE 313 group 
but was about one half the risk for the ApoE 4 / 4  
group (Z  = 2.10, p = 0.036). In contrast, among fe- 
male relatives the risk for the ApoE 3/4 group was 
nearly twice the risk for the ApoE 3 / 3  group ( Z  = 
3.00, p = 0.0026) but almost identical to the risk for 
the ApoE 414 group (Fig 4).  Proportional hazards anal- 
yses revealed that male relatives of 3 / 3  and 3/4 pro- 
bands have reduced risk of A D  compared with male 
relatives of 4/4 probands (relative risk [RR] = 0.56; 
95% confidence limits = 0.35-0.91, p = 0.018). In 
contrast, female relatives of 314 and 4 / 4  probands had 
an increased risk of A D  compared with female relatives 
of 3 / 3  probands (RR = 1.90, 95% confidence limits 
= 1.36-2.66, p = 0.0002). 
Discussion 
In this sample of 549 families, the risk of A D  among 
first-degree relatives increases significantly with the 
number of ApoE ~4 alleles present in the proband. 
These results support the hypothesis that the E4 iso- 
form enhances disease susceptibility. However, the 
risk of developing AD does not correspond fully with 
the estimated proportion of ~4 carriers among the rela- 
tives in this group of families. Among relatives of 
ApoE 3/4 probands, women have approximately twice 
the risk as men of developing A D  by a given age. 
Approximately two thirds of the probands in this 
study were ascertained from specialty clinics for mem- 
ory disorders participating in the MIRAGE Study and 
these subjects may not be representative of all AD 
patients. Clinic patients tend to have younger ages at 
onset and be more educated than others. Although age 
at onset may be related to ApoE genotype, it is unlikely 
that either of these factors distorted the association 
between ApoE genotype of the proband, familial clus- 
tering of AD, and gender. It is also possible that clinic 
patients are more likely to report a family history of 
dementia [32]. However, at age 70 the lifetime risk of 
A D  in the relatives of MIRAGE patients (30.9 ? 
2.5c/r) was less than the corresponding risk to relatives 
of the Dutch population-based patients (38.8 ? 
6.29ii), but the difference was not significant ( p  = 
0.24). Another concern is that only one third of the 
MIRAGE patients at these centers were genotypcd for 
ApoE. Although most of the remaining subjects were 
either deceased or  no longer followed in the clinic, 
refusal of some to donate a blood sample may have 
introduced a selection bias associated with perceptions 
of family history of AD. This is also unlikely because 
the 30.9% risk for relatives of the 378 MIRAGE pa- 
tients in this study is nearly identical to the correspond- 
ing risk estimated for relatives of the total sample of 
1,694 MIRAGE patients (32.9 2 1.3%) [33]. 
The observations that relatives of ApoE 3/3 pro- 
bands have a 38% lifetime risk (to age 96) of devel- 
oping AD, but only 13% of these individuals are pre- 
dicted to have at least one ~4 allele, suggest that 
familial factors (genetic or  nongenetic) independent of 
ApoE contribute substantially to disease susceptibility. 
van Duijn and coauthors [8} reported that both the 
number of ~4 alleles and a family history of a first- 
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degree relative with memory problems influence risk 
of early-onset AD, but there is disagreement whether 
these two factors act additively or interact in the pre- 
diction of AD [34, 351. It is likely that ApoE interacts 
with other molecules in the pathophysiology of AD 
given its important role in a variety of physiological 
pathways [36, 37). Our lifetime risk data for ApoE 
313 probands and for relatives of affected members of 
families with familial late-onset A D  137, 401, and ge- 
netic linkage studies C37, 38)  support the existence of 
other AD genes that may interact with ApoE. 
Although our data demonstrate a significant increase 
in risk of disease among relatives with dose of e4 in 
the proband (see Table 3) ,  the 7 to 10% increase in 
risk for each e4 allele in the proband is much less 
than expected if the E4 isoform was sufficient to cause 
disease in all people. In fact, the lifetime risk estimate 
of  44c/; among first-degree relatives of ApoE 4 / 4  pro- 
bands suggests that after adjusting for censored obser- 
vations, as many as 50% of people having at least one 
~4 do not develop AD. Approximately 66% of the 
relatives in this group are predicted to have the ApoE 
3/4  genotype and 24% to be e4 homozygotes. Since 
none of  the relatives were typed for ApoE, we cannot 
compare the risk of disease for relatives with 3/4  ver- 
sus 414 genotypes. However, the fact that the risk by 
age 90 to relatives of 3/4  probands, of whom only 7% 
are predicted to be ~4 homozygotes, is only 4.4%. 
lower than the risk to relatives of 4 / 4  probands (see 
Table 4 ) ,  indicates that a substantial proportion of per- 
sons with the 4 / 4  genotype are cognitively normal at 
a very old age. This conclusion is supported by cross- 
sectional population-based studies [4 1, 42). The dis- 
parity between risk of disease and proportion of ~4 
carriers may be attributed to an underestimate of de- 
mentia among relatives. This explanation is unlikely 
for two reasons. First, to maximize diagnostic certainty 
among relatives, we restricted our analysis to first- 
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degree relatives, used mutliple informants, and re- 
viewed medical and other records for all subjects sus- 
pected to have dementia. Second, since the relatives 
of ApoE 313 probands have a higher risk of disease 
than the expected proportion of ~4 carriers, the degree 
of underestimation would have to vary by ApoE geno- 
type, and there are no apparent reasons for this. 
The finding that relatives of probands having ApoE 
genotype 212 or 213 have the same risk as relatives of 
ApoE 313 probands does not support the evidence for 
a protective effect of the e 2  allele on the risk of A D  
[42-461. However, our results are also not conclusive 
for the hypothesis of an increased risk associated with 
this allele C47-491. There are several explanations why 
our analyses do not distinguish between these two 
hypotheses. First, the proportion of relatives having 
~ 4 ,  and the 414 genotype in particular, is the same for 
ApoE 212, 213, and 313 probands. Thus, although the 
proportion of relatives of ApoE 212 or 213 probands 
having ~2 is estimated to be six to seven times higher 
than among relatives of 313 probands, in the collective 
group of relatives whose individual genotypes are un- 
known, the effect (positive or negative) of ~2 may have 
been masked by the detrimental effect of ~ 4 .  Alterna- 
tively, a much larger sample of e 2  probands may be 
needed to demonstrate a difference in lifetime risk of 
A D  among relatives. It is also plausible that the effect 
of ~2 on risk of AD may depend on other genetic 
or environmental factors. Our study sample includes 
patients from various ethnic backgrounds and geo- 
graphic regions. 
The trend of younger onset age among affected rela- 
tives with dose of e4 in the proband was nor significant. 
In fact, because in our procedure mean onset age was 
estimated simultaneously with the lifetime risk, the 
means would have been even more similar had the 
maximum onset ages for each group been the same. 
Lack of a dose effect reflects, perhaps, a limitation of 
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our study design for relating ApoE genotype in pro- 
bands to risk of illness and expression in relatives. Al- 
ternatively, previous estimates for the onset age distri- 
bution of each ApoE genotype were biased because 
they were derived from members of families with late- 
onset familial AD {14].  This explanation is unlikely 
because although the distributions estimated from AD 
patient samples may be skewed from the true distribu- 
tions, differences between ApoE genotype groups 
should be the same. Moreover, a dose effect of ~4 on 
age at onset is also supported by family studies [SO- 
521. A more plausible explanation for our findings is 
that age at onset of AD is determined by a complex 
interaction of genetic and environmental factors (V. S. 
Rao and colleagues, unpublished manuscript 1995) of 
which only two (ApoE genotype and sex) were consid- 
ered in the present study. 
A gender difference in lifetime risk of AD among 
relatives of ~4 heterozygotes was observed previously 
in a study of 52 families with late-onset familial AD 
[5 31; however, the relative differences in risk attribuc- 
able to ApoE genotype were relatively small compared 
to other factors because men and women in those fami- 
lies lacking e 4  had a lifetime risk of AD of at least 
70%. Duara and coworkers [54] also found that the 
proportion of affected women versus affected men was 
higher for relatives of probands having the ApoE 3/4  
genotype than for relatives having the ApoE 3 / 3  geno- 
type. The apparently reduced risk of AD among male 
relatives of ApoE 3 / 4  probands may be due to the 
association of hypercholesterolemia and coronary heart 
disease with ApoE e4  [55-57]. Males with e4  who 
have an increased risk of AD may be underrepresented 
among the relatives because they are more likely than 
females to succumb to heart disease before reaching 
an age when AD would occur. However, this is proba- 
bly not an explanation for our findings. Data from mid- 
dle-age (mean = 48.7 ? 10.2 years, range = 21-77 
years) and elderly (mean = 76.4 ? 5.9 years, range 
= 67-95 years) cohorts in the Framingham Study re- 
vealed only a slight reduction of the e4 allele frequency 
with age [31, 423. Other studies showing a significant 
age-related decrease in ~4 did not indicate gender dif- 
ferences 141, 58, 591. 
Rather, our results suggest the presence of a sex- 
modification effect of the ApoE 4 isoform on disease 
susceptibility. Among women, a single copy of the ~4 
allele appears to be sufficient to elevate disease risk 
from baseline (i.e., risk of disease among persons hav- 
ing the ApoE 3 / 3  genotype), whereas among men, a 
double dose of € 4  is necessary to attain the same in- 
crease in risk. This hypothesis is supported by our 
findings from segregation analysis which suggest that 
after adjusting for gender differences in longevity, 
women are innately more susceptible than men to AD 
[60]. Factors that may be specific to women, or act 
differently in women than men, and modify the delete- 
rious effects of ApoE 4 include hormones such as es- 
trogen [61], antiinflammatory drugs [62) ,  and choles- 
terol [36f. Studies of the interaction of these factors 
with ApoE may provide important clues for preventing 
onset of the disorder. 
Our findings have important clinical implications. An 
individual may have an affected parent or sibling who 
is diagnosed with AD and wishes to know his or her 
risk based on the ApoE genotype of the affected family 
member. On the basis of data reported by Corder and 
associates [43], the sensitivity for diagnosing AD from 
the detection of two ~4 alleles is 6957 and the specific- 
ity is 72%’ [lS]. Our results suggest that the predictive 
value of ApoE genotype could be improved by incor- 
porating information on the consultant’s sex and resid- 
ual genetic factors. Until tests for other genetic factors 
for AD are developed (amyloid precursor protein 
[APP} mutations and defects in chromosomes 1- and 
14-linked genes are apparently rare causes of AD), one 
could incorporate a quantitative assessment of the per- 
son’s family history [63] into the diagnostic test. 
~~ 
This work was supported in part by National Institutes of Health 
grants ROI-AG07029 (to L. A. F.), P3O-AG101.30 (to the Alzheimer 
Disease Center at Emory University), RO1-AG1 1503 (to R. C. G.) ,  
AGO5142 (to the Alzheimer Disease Research Center at the Univer- 
sity of Southern California), PiO-AGO5 134 (to J .  H .  G.), and R01- 
NS3 1 1  53 (to J.  L. H.): a Zenith Award from the Alzheimer Associa- 
tion (to J. L. H.); The Netherlands Organization for Scientific 
Research (NWO);  and the Flemish Biotechnology Program. Dr 
Wells was supported by a VA Merit Review. Dr van Broeckhoven 
is a research associate of the National Fund for Scientific Research 
(NFSR), Belgium. 
We thank Elizabeth Foley. Beth Souza, Dr Nicola Lautenschlager, 
D r  Randi Jones, and Kathy Martelli for collecting fidmily history 
information, and Jemma Williams for assistance in preparing the 
manuscript. Drs Wim Schulte, Teun Tanja. Rob Haaxma, Arie Lame- 
ris, Rolf Saan, and Helen de Bruijn, Micheline de Haes, Jeanette 
Kamman, Hilda Kornman, Hanneke van Meurs, and Caroline Vd- 
kenburg were involved in collecting the Dutch data. Hans van der 
Boom. Peter de Knijff, Louis Havekes, hfarc Cruts, and Anita 
Wehnert are acknowledged for ApoE typing the Dutch patients. Dr 
Chris Zarow extracted DNA from USC autopsy samples. Brain us- 
sue for the Bedford patients was obtained from the GRECC brain 
bank. 
References 
I .  Evans DA, Funkensrein H H ,  Albert MS, er al. Prevalence of 
Alzheimer’s disease in a community population of older persons. 
2. Brereler MMB, Claus JJ, van Duijn CM, et al. Epidemiology of 
Alzheimer’s disease. Epidemiol Rev 1992; 14:>9-82 
3 .  Goate A, Chartier-Harlin M-C, Mullan M, K t  al. Segregation of 
a missense mutation in the amyloid precursor protein gene with 
familial Alzheimer’s disease. Nature 199 1;349:’04-706 
4.  Mullan M, Crawford F, Houlden H,  et al. A pathogenic muta- 
tion for probable Alzheimer’s disease in the APP gene at the 
N-terminus of P-amyloid. Nature Genet 1992;1:345-347 
5. Murrell J, Farlow M, Ghetti B, Benson M. A mutation in the 
.JAMA 1989;262:2 S S 1-25 56 
806 Annals of Neurology Vol 38 No 5 N o v e m b e r  1995 
amyloid precursor protein associated with hereditary Alzhei- 
mer’s disease. Science 1991;254:9-99 
6. Sherrington R, Rogaev El, Liang Y, et al. Cloning of a gene 
hearing niissense mutations in early-onset familial Alzheimer’s 
disease. Nature 1995;.375:754-760 
7.  Levy-Lahad E, Wasco W, Poorkaj P, e t  al. Candidate gene for 
chromosome 1 familial Alzheimer’s disease locus. Science 1995; 
8. van Duijn CM. de Knijff P, Cruts M ,  et al. Apolipoprotein E4 
allele in a population-based study of early-onsct Alzheimer’s 
&ease. Nature Genet  1994;7: ’4-78 
9. Saunders AM, Stritrmatter WJ, Schmechel D. et  al. Association 
of apolipoprotein E allele ~4 with late-onset familial and spo- 
radic Alzheimer’s disease. Ncurology 1993;43:1467-1472 
10. Roses AD. Apolipoprotein E affects the rate of Alzheimer dis- 
ease expression: @myloid burden is a secondary consequence 
dependent on APOE genotype and duration of disease. J Neu- 
ropathol Exp Neurol 1994;53:429-43‘ 
11. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform- 
specific interactions of apolipoprotein E with riau and phosphory- 
lated tau: implications for Alzheimer disease. Proc Natl Acad 
Sci USA 199~;91:11183-11186 
12. Strittmatter WJ, Weisgraber KH. Goedert M, et al. Hypothesis: 
microtubule instability and paired helical filament formation in 
the Alzheimer disease brain as a function of apolipoprotein E 
genotype. Exp Neurol 1994;125:163-171 
13 .  Reheck GW, Reitcr JS, Strickland DK, Hynian BT. Apcilipo- 
protein E in sporadic Alzheimer’s diseae: allelic variation and 
receptor interactions. Neuron 1993: 1 1 :575-580 
14.  Corder EH, Saunders AM, Stritrmatter WJ, er al. Gene dose of 
apolipoprotein E type 4 allele and the risk of Alzheimer’s disease 
in late onset families. Science 1993;261:92 1-923 
15. van Goo1 WA, Hijdra A. Diagnosis of Alzheimer’s disease by 
apolipoprotein E genotyping. Lancet 1994;344.275 
16. Farrer LA, Cupples LA, Blackburn S, et al. Interrater agreement 
for diagnosis of Alzheimer disease: the MIRAGE study. Neurol- 
ogy 1994 ;.t4 :65 2-656 
1’. McKliann G ,  Drachman D ,  Folstein M, et al. Clinical dignosis 
of Alzheimer’s disease: report of the NINCDS-ADRDA work 
group under the auspices of the Department of Health and 
Human Services Task Force on  Alzheimer’s Disease. Neurology 
1084;34:939-945 
18. van Duijn CM, Farrer LA, Cupples LA, Hofman A. Genetic 
transmission for Alzheimer disease among patients identified in 
a Dutch population based survey. J Med Genet 1993;30:040- 
646 
19. Hofman A, Schulte W, Tanja TA, et al. History of dementia 
and Parkinson’s disease in 1st-degree relatives of patients with 
Alzheimer’s disease. Neurology 1 ‘)89;39: 1589-1 592 
20. Farrer LA. OSullivan DM, Cupples A, et al. Assessment of 
genetic risk for Alzheimer’s disease among hrst-degree relatives. 
Ann Neurol 1989;25:485-493 
21. Farrer LA, Myers R H ,  Connor L, e t  al. Segregation analysis 
reveals evidence of a major gene for Alzheimer disease. Am J 
Hum Genet  1991;48:1026-1033 
22. Wenham PR, Price W H .  Blundell G. Apolipoprotein E geno- 
typing by one-stage PCR. Lancet 1991;337:1158-1159 
23. Locke P, Conneally PM, Tanzi RE, et al. APOE and Alzheimer 
disease: examination of allelic association and effect on age at 
onset in both early and late onset cases. Genet Epidemiol 1995; 
12:83-92 
24. Hixson JE, Vernier DT. Restriction isotyping of human apolipo- 
protein E by gene amplification and cleavage with Hhal. J Lipid 
Res 1990;31:545-548 
25. Cupples LA, Risch N, Farrer LA, Myers RH. Estimation of age 
at onset with missing information on  onset. Am J H u m  Genet 
1991;49:76-87 
269:973-977 
26. Kaplan EL, Meier P. Non-parametric estimation from incom- 
p l e t ~  observations. J Am Stat Assoc 1958;53:457-481 
27. Sokd RR, Rohlt FJ. Biometry. San Francisco: W H  Freeman, 
1981 
28. KalbHeisch JD,  Prentice RL. The  statistical analysis of failure 
rime data. New York: Wiley, 1980 
29. Cox DR. Regression models and life-cables (with discussion). 
J R Stat Soc Ser B 1972;34:187-220 
30. SAS User’s Guide: Statistics. Cary, NC. SAS Institute. 1990 
-31. Ordovas JM, Litwack-Klein L, Wilson PWF, ct al. Apolipopro- 
rein E isoform phenotyping methodology and population 
frequency with identification of apoEl and apoE5 isoforms. J 
Lipid Res 1987;28:371-380 
32. Rocca WA, Amaducci L. Epidemiology of Alzheimer’s disease. 
In: Anderson DW, ed. Neuroepidemiologp: a tribute to Bruce 
Schoenberg. Boca Raton: CRC Press, 1991:55-90 
33. Lautenschlager NT.  Cupples LA, Rao VS. et al. Risk of demen- 
tia among rdatives of Alzheimer’s disease patients in the MI- 
RAGE study: what is in store for the “oldest old”! Neurology; 
1966 ( i n  press) 
34. Jarvik GP,  Wijsman EM. Alzheimer’s disease and the family 
effect. Nature Genet 1994;8:115 
35. van Duijn C, Van Broeckhoven C. Alzheimer’s disease and the 
family effect-reply. Nature Genet 199.1;8: 115 
36. Jarvik GP,  Wijsman EM, Kukull WA, et al. Interaction of apoli- 
poproteiii E genotype, total cholesterol level, and sex in predic- 
tion of Alzheimer disease in a case-control study. Neurology 
37. Kamhoh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE“4 
Associated Alzheimer’s disease risk is modified by a l-antichy- 
motrypsin polymorphism. Nature Genet 1995; 10:486-488 
38. Farrer LA, Myers R H ,  Cupples LA, et al. Transmission and age 
at onset patterns in familial Alzheimer‘s disease: evidence for 
heterogeneity. Neurology 1990;40: 395-403 
39. Locke PA, Haines JL, Corder EH, et al. Methods for detecting 
additional genes underlying Alzheimer disease. Am J Hum 
Genet 195)4;55:A194 
40. Yu C-E. Payanii H, Olson JM, et al. The  apolipoprotein E/C/ 
CII gene cluster and late-onset Alzheimer disease. Am J Hum 
Genet 1994;54:0i 1-642 
41. Kuusisto J. Koivisto K,  Kervinen Mykkinen L, er al. Association 
of apolipoprotein E phenotypes with late onset Alzheimer’s dis- 
ease: population based study. BMJ 1994;309:036-638 
42.  Myers R H ,  Schaefer EJ, Wilson PWF, et al. Apolipoprotein E 
allele 4 is associated with dementia in a population based study: 
the Framingham Study. Neurology 1995 (in press) 
43. Corder EH, Saunders AM, h s c h  NJ, et  al. Protective effect of 
apolipoprotein E type 2 allele for late onset Alzheimer disease. 
Nature Genet 1994;7:180-184 
44. Chartier-Harlin M-C, Parfitt M,  Legrain S, et al. Apolipoprotein 
E, E4 allele as a major risk factor for sporadic early and late-onset 
forms of Alzheimer’s disease: analysis of the I9q13.2 chromo- 
somal region. H u m  Mol Genet 1994;3:569-574 
45.  Talbot C, Lendon C, Craddock N ,  et al. Protection against Alz- 
heimer’s disease with apoe ~ 2 .  Lancet 1994;343: 1432-1433 
46. Smith AD, Johnston C, Sim E. et al. Protective effect of apoE 
122 in Alzheimer’s disease. Lancet 1994;344:473-4?4 
47. Sorbi S, Nacniias B, Forleo P. et al. ApoE allele frequencies in 
Italian sporadic and familial Alzheimer’s disease. Neurosci Lett 
1994;1?7: 100- 102 
48. Maestri G ,  Ottman R, Stern Y, et al. Apolipoprotein E and 
Alzheimer’s disease: ethnic variation in genotypic risk. Ann 
Neurol 1995;37:254-259 
49. van Duijn CM, d e  Knijff P, Wehnerr A. et al. The  apolipopro- 
rein E € 2  allele is associated with an increased risk of early-onset 
Alzheimer’s disease and a reduced survival. Ann Neurol 1995; 
1995;45: 1092- 1096 
37:605-610 
Farrer et al: ApoE Genotype in AD 807 
5 0 .  Borgaonkar DS, Schmidt LC. Martin SE, er al. Linkage of Iate- 
onset Alzheimer disease wirh apolipoprorein E type 4 on chro- 
mosome 19. Lancer 1093;342:625 
5 I .  Hardy J,  Houlden H ,  Collinge J ,  et al. Apolipoprotein E geno- 
type and Alzheimer’s disease. Lancet 199.3;342:737-738 
5 2 .  St.  George-Hyslop P, McLachlan DC, TudaT,  et al. Alzheimer’s 
disease and possible gene interaction. Science 1994;263:5 3- 
5 3 .  Payami H, Monree KR, Kaye JA. er al. Alzheimer’s disease. 
apolipoprotein t-4, and gender. JAMA 1994;L’l:l3l6-1317 
56. Duara R, Barker WW, Lopez-Alberola R, et al. Alzheimer’s 
disease: interaction of apolipoprotein E genotype, family history 
ofdenientia, gender, education. ethnicity, and age at onset. Neu- 
rology 1996 ( in  press) 
33. Leren TP, Borresen AL, Berg K, et al. Incrcased frequency of 
the apolipoprotein E-4 isoform in inale subjects with multifimo- 
rial hypercholesrerolcmia. Clin Genct 1985;27:458-462 
5 6 .  Lenzen HJ. Assinann G, Buchwalsky R, Schulte H. Association 
of apolipoprotein E polymorphism. low-density lipoprotein iho-  
lesterol, and coronary artery disease. Clin Chem 1086;32:’78- 
7x1 
57.  Van Bockxmeer FM, Mamotre CD. Apolipoprotein epsilon 4 
homozygosity in young men wirh coronary heart disease. Lancet 
1992;360:879-880 
58. Davignon J. Bouthillier D, Ncstruck A, Sing C.  Apolipoprotein 
E polymorphism and atherosclerosis: insight from a study in 
octogenarians. Trans Am Clin Assoc 1088;99: 100-1 10 
59. Cauley JA, Eichner JE, Kamboh MI, et al. ApoE allele frequen- 
cies in younger (age 42-30) vs older (age 65-90) women. Genet 
Epidemiol 1993;t0:27-.3 
60. Rao VS, van Duijn CM, Connor-Lacke L, et al. Multiple etiolo- 
gies for Alzheimer disease are revealed by segregation analysis. 
Am J Hum Genet 1994;55:991-1000 
61. Paganini-Hill A. Henderson VW. Estrogen dehciency and risk 
of Alzheimer’s disease in women. Am J Epidrmiol 1994;140. 
256-261 
62. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association 
of anti-inflammatory treatments and Alzheimer’s disease: initial 
results o f  a co-twin control study. Neurology lW;44 .227-232  
63. Farrer LA. Cupples LA. Estimating the probability for major 
gene AIzheimer disease. Am J Hum Genet 1994;54:374-383 
808 Annals of Neurology Vol 38 No 5 November 1995 
